Importantly, these findings highlight that protein levels of YB-1 and MTA1 do not positively correlate with metrics associated with aggressive prostate cancer, but instead raise the possibility that these biomarkers may be independent predictors of disease outcomes in prostate cancer patients undergoing localized therapy. The gene discussed is YBX1; the disease is Familial prostate cancer.